[{"id":"19720944-036d-444d-865d-588a5ff231f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836429","created_at":"2021-04-08T13:52:42.896Z","updated_at":"2024-07-02T16:34:59.219Z","phase":"Phase 1","brief_title":"Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease","source_id_and_acronym":"NCT04836429","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Photofrin (porfimer sodium)"],"overall_status":"Suspended","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 03/17/2025","study_completion_date":" 03/17/2025","last_update_posted":"2024-06-04"},{"id":"2974135e-ebdf-4d64-8099-6f751a860dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04590664","created_at":"2021-01-18T21:53:39.246Z","updated_at":"2024-07-02T16:35:17.654Z","phase":"Phase 1/2","brief_title":"Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma","source_id_and_acronym":"NCT04590664","lead_sponsor":"Emory University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Visudyne (verteporfin)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2024-02-26"},{"id":"cf834b01-5b9b-4c32-bb23-b221bf405680","acronym":"","url":"https://clinicaltrials.gov/study/NCT02653976","created_at":"2021-01-18T12:55:59.721Z","updated_at":"2024-07-02T16:35:22.114Z","phase":"Phase 2","brief_title":"A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT02653976","lead_sponsor":"Solasia Pharma K.K.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zinapar (darinaparsin)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 03/25/2016","start_date":" 03/25/2016","primary_txt":" Primary completion: 10/11/2020","primary_completion_date":" 10/11/2020","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2024-01-26"},{"id":"8f07f453-2b2f-43e3-acb3-b43491e93deb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00888615","created_at":"2021-01-18T03:24:06.456Z","updated_at":"2024-07-02T16:36:22.721Z","phase":"Phase 2","brief_title":"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00888615","lead_sponsor":"GOG Foundation","biomarkers":" CYP1A2","pipe":"","alterations":" ","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • elesclomol (STA-4783)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 12/13/2010","start_date":" 12/13/2010","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 08/31/2016","study_completion_date":" 08/31/2016","last_update_posted":"2021-10-20"}]